Cadrenal Therapeutics (CVKD) Total Non-Current Liabilities (2022 - 2023)
Cadrenal Therapeutics (CVKD) posted Total Non-Current Liabilities of -$3.6 million for Q4 2023, down 282.27% sequentially from $1.9 million in Q4 2022, and down 282.27% YoY from $1.9 million in Q4 2022.
Cadrenal Therapeutics (CVKD) Total Non-Current Liabilities (2022 - 2023) Analysis & Trends
Cadrenal Therapeutics has reported Total Non-Current Liabilities for 2 years, with the latest figure at -$3.6 million in Q4 2023.
- Quarterly Total Non-Current Liabilities fell 282.27% year-over-year to -$3.6 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was -$3.6 million (down 282.27% YoY) and the FY2023 annual result came in at -$3.6 million, down 282.27% from the prior year.
- Total Non-Current Liabilities fell to -$3.6 million in Q4 2023 per CVKD's latest filing, from $1.9 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $1.9 million in Q4 2022 and troughed at -$3.6 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.79 Bn | 131.94 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.74 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 59.32 Bn | 54.18 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.81 Bn | 28.50 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.56 Bn | 26.40 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 9.32 Bn |
| 10 | Cadrenal Therapeutics | 4.66 Mn | 2.26 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -3.55 Mn |
| Dec 31, 2022 | 1.95 Mn |